-
Heilongjiang Provincial Hospital Eye Hospital focuses on the training of primary ophthalmology talents
Time of Update: 2021-07-10
In response to the "14th Five-Year Plan" eye health plan and further improve the three-level blindness prevention and eye health service system, from April 8 to April 11, 2021, Heilongjiang Provincial Hospital joined hands with Zeiss’s “Guangming City and County” Cataract Capacity Building Project.
-
Type 1 diabetes research drug TTP399 was awarded the title of breakthrough therapy by FDA
Time of Update: 2021-07-10
On April 13, the US FDA granted vTv Therapeutics' research drug TTP399 the title of breakthrough therapy for type 1 diabetes (T1D) .
Reference source: FDA Grants vTv's Type 1 Diabetes Drug Breakthrough Therapy Designation
-
Boston Scientific's innovation and exploration of "first and first trial" continues to help the construction of Hainan Free Trade Port
Time of Update: 2021-07-10
Today, Boston Scientific, with its many star products, once again appeared at the "Never Ending" International Innovative Medicine and Equipment Exhibition in Boao Lecheng International Medical Touri
-
Innovent and Eli Lilly announce the results of a Phase III clinical study of Dabexel in the second-line treatment of squamous non-small cell lung cancer at the 2021 AACR online annual meeting
Time of Update: 2021-07-10
ORIENT-3 is a randomized, open-label, multi-center, parallel-controlled phase III clinical study of sintilimab versus docetaxel for the second-line treatment of advanced squamous non-small cell lung cancer (sqNSCLC) .
The ORIENT-3 study confirmed that Sintilimab can significantly improve the overall survival benefit of second-line squamous NSCLC patients, which has important clinical significance.
-
The first domestic Johnson & Johnson Eyecare "Catalys" was successfully installed
Time of Update: 2021-07-10
This is the first "Catalys" equipment installed by Johnson & Johnson EyeLife in China after obtaining the registration approval from the National Medical Products Administration at the beginning of this year .
-
Biolight intends to spend 11.7 million yuan to establish a joint venture to develop the blood purification market
Time of Update: 2021-07-09
Company"), with a registered capital of RMB 18 million .
00% of the registered capital of the joint venture company; Zhili Medical invested RMB 6.
-
Nuocheng Jianhua held the first investor R&D day
Time of Update: 2021-07-09
At the same time, the company has established a complete commercialization team to promote obritinib to benefit more Chinese patients; in addition to the approval of obritinib, the company has developed more than 10 drug pipelines that are progressing smoothly.
-
Huahai Pharmaceutical's Valsartan and Amlodipine Tablets and Topiramate Tablets obtained "Drug Registration Certificate"
Time of Update: 2021-07-09
Up to now, the company has invested approximately RMB 18,442,600 in R&D expenses in the R&D project of valsartan and amlodipine tablets .
Up to now, the company has invested approximately RMB 8,264,400 in R&D expenses in the research and development project of topiramate tablets .
-
Teresa is approved in China for adjuvant treatment of patients with early-stage EGFR-mutant lung cancer
Time of Update: 2021-07-09
" Dave Fredrickson, Global Executive Vice President of AstraZeneca and Head of Oncology Division, said: "The rapid approval of osimertinib in China is part of the curative treatment plan for early EGFR-mutant lung cancer, highlighting the considerable future in this field.
-
Buy, buy, buy!
Time of Update: 2021-07-09
A few days ago, Thermo Fisher Scientific announced that it will acquire PPD, a world-renowned CRO provider of clinical research services, for a cash price of up to $17.
Thermo Fisher to buy PPD, in a cash deal valued at $17.
-
Luye's Jimai Biotechnology releases research progress on hydrogel-encapsulated TLR9 agonists
Time of Update: 2021-07-09
Luye Life Sciences Group, a subsidiary of Luye Life Sciences Group, which focuses on the development of nucleic acid therapeutic drugs, published an electronic poster at the 2021 American Association for Cancer Research (AACR) annual meeting entitled "Hydrogel-encapsulated TLR9 agonists have long-lasting tumors" Growth inhibition, and prolong the survival of CT26 tumor-bearing mice" clinical progress .
-
Lechun Biotech and Renolite signed a strategic cooperation agreement
Time of Update: 2021-07-09
And this strategic cooperation with Lechun Biotechnology is also aimed at building a single-use system film supply channel, aiming to provide localized production capacity, improve the long-term stability of the supply chain, and look forward to providing better domestic biotechnology companies The service supports the rapid, healthy and stable development of China Biopharmaceuticals .
-
Simcere's clinical trial application for brain edema drug SIM-307 was approved
Time of Update: 2021-07-09
On April 14, Simcere announced that its clinical trial application for the treatment of acute ischemic stroke complicated by cerebral edema, SIM-307, has been approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration .
-
TJD5 announced that the results of the Phase 1 clinical study of TJD5 in the United States were selected for the ASCO annual meeting for display and report
Time of Update: 2021-07-09
At the 2021 American Society for Cancer Research (AACR) annual meeting, Cosmos Bio focused on showing the new protein structure and molecular mechanism of uliledlimab binding to CD73, as well as its single-drug and anti-PD-(L)1 antibody combination.
-
Fosun Pharma: HLX26 for the treatment of solid tumors and lymphoma was approved for clinical trials
Time of Update: 2021-07-09
On April 15, Fosun Pharma announced that recently, the company’s holding subsidiary, Fuhong Henlius, and its holding subsidiary Hanlius Pharmaceuticals received the State Drug Administration’s approval for its development of recombinant anti-LAG-3 humanized monoclonal Approval of antibody injection for the treatment of solid tumors and lymphomas for clinical trials .
-
Microchip Technology: Cioroni is approved for clinical trial in the treatment of relapsed/refractory SCLC
Time of Update: 2021-07-09
Theoroni is a new chemical structure with global patent protection independently designed and developed by the company, which belongs to a multi-target multi-pathway selective kinase inhibitor .
It is a small-molecule anti-tumor original innovative drug that can selectively inhibit multiple kinase targets such as Aurora B, CSF1R and VEGFR/PDGFR/c-Kit .
-
Guangshengtang Jinge Sildenafil Citrate Tablets Obtained Drug Manufacturing Registration Certificate
Time of Update: 2021-07-09
In 1998, it was approved by the US FDA to be marketed in the US for the first time under the trade name ** (Viagra).
were approved for marketing in China in 2000 .
-
Yangtze River was fined 764 million!
Time of Update: 2021-07-09
According to investigations, from 2015 to 2019, Yangtze River Pharmaceutical Group reached agreements with downstream companies such as drug wholesalers and retail pharmacies by signing cooperation agreements, issuing price adjustment letters, and oral notices across the country (excluding Hong Kong, Macao and Taiwan regions).
-
What is the way out for Ganli Pharmaceutical's revenue and profit growth in 2020 under the pressure of centralized production of double-lowering insulin?
Time of Update: 2021-07-09
At present, the domestic insulin market is highly concentrated, mainly occupied by Novo Nordisk, Sanofi, Eli Lilly, Tonghua Dongbao, Ganli Pharmaceutical, and United Laboratories .
Observation of Ganli Pharmaceutical's 2017-2020 report found that its insulin preparation sales revenue accounted for 96.
-
Danaher supports the 6th National Clinical Innovation and Invention Competition
Time of Update: 2021-07-09
Zhu Qingsheng, former vice minister of the Ministry of Health, and Fan Jia, president of Zhongshan Hospital, gave speeches, encouraging clinical workers to forge ahead, pioneer and innovate, unite the power of enterprises and capital, respond to the call of the country, quickly realize the transformation of results, benefit the people, and continuously improve our country Medical standards and the level of transformation of scientific research and technological achievements .
